Kulkarni Samarth's Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Feb 21, 2024
- Accession no.
- 0000950170-24-018174
- Filed
- Feb 21, 2024
- Trade date
- Feb 18-20, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $507.5K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kulkarni SamarthCIK 0001682019 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2024 | Common Shares | MOption exerciseAcquired | +13,250 | –F1 | – | 200,627 | Direct | |
| Feb 20, 2024 | Common Shares | SSaleDisposed | −6,370 | $79.67 | −$507,497.9 | 194,257 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 18, 2024 | Common Shares | MOption exerciseDisposed | −13,250 | –F1 | – | 26,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.